Quince Therapeutics, Inc. (QNCX): Results of Operations and Financial Condition
Quince Therapeutics, Inc. (QNCX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
How this was made
The 30-second read
Why it matters
The filing combines (1) a completed M&A transaction that brings LAM-001 into Quince’s pipeline, (2) a new $115M upfront private placement with potential warrant-driven upside, and (3) updated cash runway guidance, alongside quarterly financials and trial timing expectations.
Market read
Traders can update positioning based on the completed acquisition, the size and structure of the financing, and the stated funding runway, while monitoring the next major clinical catalysts in 2027-2028.
What to watch
G&A jumped materially due to acquisition-related stock-based comp and restructuring, and the net loss widened sharply, which can offset positive pipeline headlines.
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
The company completed the Orphai acquisition and raised $115 million in upfront gross proceeds, supporting a stated cash runway through the end of 2028, while quarterly net loss widened to $75.5 million and G&A expense increased to $16.6 million.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenseother | $5.5 million | – | – |
| General and administrative expenseother | $16.6 million | – | – |
| Net lossother | $75.5 million | – | – |
| Net loss per shareother | $12.31 per basic and diluted share | – | – |
| Shares outstandingother | 978,022 shares of common stock | – | – |
| Cash and cash equivalentsother | $116 million | – | – |
through the end of 2028 outlook
- NoteCash position expected to be sufficient to fund operations through the end of 2028.
- NoteTopline data from the Phase 2b trial of LAM-001 in PH-ILD anticipated in the first quarter of 2028.
- NoteData from the Phase 2 trial of LAM-001 in BOS expected in the first quarter of 2027.
- NotePhase 2 trial of LAM-001 in SAPH anticipated to begin in late 2026, with data expected in the fourth quarter of 2028.
What drove it
- R&D expense decreased primarily because of lower eDSP program costs following the wind down of that program.
- LAM-001 costs increased $0.8 million as a result of study start-up costs.
- G&A expense included $9.1 million in non-cash stock based compensation from a one-time charge related to the assumption of historical options upon closing of the acquisition.
- G&A expense also increased due to an increase of $4.4 million in professional fees associated with the Quince restructuring before completion of the acquisition.
- Clinical sites have been activated and the company is actively screening subjects for the Phase 2b LAM-001 trial in PH-ILD.
- The Phase 2 LAM-001 trial in BOS is fully enrolled.
Concerns
- Net loss was $75.5 million for the three months ended June 30, 2026, compared to a net loss of $16.0 million for the three months ended June 30, 2025.
- G&A expense increased to $16.6 million from $3.3 million, driven by a one-time stock-based compensation charge and higher professional fees.
- Key LAM-001 clinical data milestones extend to the first quarter of 2027 for BOS, the first quarter of 2028 for PH-ILD, and the fourth quarter of 2028 for SAPH.
What to watch
- Phase 2 LAM-001 BOS data anticipated in the first quarter of 2027.
- Initiation of the Phase 2 LAM-001 SAPH trial anticipated in late 2026.
- Phase 2b LAM-001 PH-ILD topline data anticipated in the first quarter of 2028.
- Phase 2 LAM-001 SAPH data expected in the fourth quarter of 2028.
- Cash runway expected through the end of 2028 and potential exercise of warrants for up to an additional $83 million.
Balance sheet and cash flow
- Cash and cash equivalents were $116 million as of June 30, 2026.
- The private placement generated gross upfront proceeds of $115 million.
- The private placement yielded net proceeds of $103.6 million after deducting placement agent and other offering expenses of $11.4 million.
- The company disclosed potential for up to an additional $83 million upon exercise of warrants, including warrants issued to former Orphai stockholders.
- Cash is expected to fund operations through the end of 2028.
Analysis
Quince reported a quarter defined by the completion of its stock-for-stock merger with Orphai and the addition of LAM-001 to its pipeline. The company concurrently closed a private placement with $115 million in gross upfront proceeds and $103.6 million in net proceeds after $11.4 million of placement agent and other offering expenses. Cash and cash equivalents were $116 million at June 30, 2026, and management stated that this position is expected to fund operations through the end of 2028.
Operating expenses reflect both portfolio transition costs and transaction-related charges. R&D expense declined to $5.5 million from $6.6 million, primarily because eDSP program costs decreased as that program was wound down. This was partly offset by a $0.8 million increase in LAM-001 costs related to study start-up. G&A expense increased sharply to $16.6 million from $3.3 million, including $9.1 million of non-cash stock based compensation associated with the assumption of historical options in the acquisition and an increase of $4.4 million in professional fees related to restructuring.
The larger G&A burden and other reported costs coincided with a net loss of $75.5 million, versus $16.0 million in the prior-year period. Net loss per share was $12.31 per basic and diluted share, compared with $68.75 per basic and diluted share. The release notes that per-share data and share-based awards were retrospectively adjusted for reverse stock splits completed at ratios of 1-for-10 on April 10, 2026 and 1-for-20 on June 29, 2026.
The operating narrative is now centered on the clinical execution of LAM-001 across PH-ILD, BOS and SAPH. The Phase 2b PH-ILD trial has activated sites and is screening subjects, with topline data anticipated in the first quarter of 2028. The BOS Phase 2 trial is fully enrolled, with data expected in the first quarter of 2027. A SAPH Phase 2 study is anticipated to begin in late 2026, with data expected in the fourth quarter of 2028.
The Phase 2a data disclosed for LAM-001 showed a mean 6MWD improvement of 67.4 meters and a mean reduction in PVR of 33.9% at 24 weeks in PH-ILD patients. In the combined evaluable PAH and PH-ILD population, the company reported a mean 6MWD improvement of 81.3 meters and a mean reduction in PVR of 28.1%. The near-term financial focus is the stated cash runway, while the principal operational milestones are the planned SAPH study initiation and the BOS data readout in the first quarter of 2027.
Management, verbatim
This was a transformational quarter for the company with a renewed focus on a differentiated, late-stage pulmonary pipeline anchored by LAM-001 as well as a strengthened balance sheet to support our development plans.
Dr. Brigette Roberts, former CEO of Orphai Therapeutics and Chief Corporate Affairs Officer of Quince Therapeutics
Not in the filing
stated, not guessed- Total revenue
- Revenue prior-year comparison
- Revenue prior-quarter comparison
- Gross profit
- Gross margin
- Operating income or loss
- Operating income or loss prior-year comparison
- Operating income or loss prior-quarter comparison
- Non-GAAP financial metrics
- Operating cash flow
- Free cash flow
- Debt
- Capital return program, including share repurchases and dividends
- Segment revenue
- Prior-quarter R&D expense
- Prior-quarter G&A expense
- Prior-quarter net loss
- Prior-quarter net loss per share
- Percentage changes for reported expenses and net loss
- Previous-release outlook for comparison
- Revenue, gross margin, operating expense, or tax-rate financial guidance
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is Quince Therapeutics’ SEC 8-K (Item 2.02) reporting Q2 2026 results plus a corporate update tied to the Orphai acquisition and concurrent financing.
Ticker impact
Quince completed the Orphai acquisition and closed a $115M private placement, adding LAM-001 and extending cash runway through end-2028.
Likely supportive for the stock on deal-and-cash clarity, but volatility remains elevated given large net loss and long-dated topline milestones.
The filing discloses a completed acquisition, a fresh $103.6M net upfront raise, and explicit funding runway, which are direct drivers of financing and pipeline risk.
Market effects
Reinforces investor appetite for inhaled mTOR-inhibition pulmonary programs and late-stage pulmonary trial progression.
Limited, mostly company-specific impact in US biotech financing and clinical pipeline sentiment.
Low; the disclosed catalysts are company-specific and not tied to global macro or regulatory actions.
Counterpoint
The cash runway through 2028 does not remove dilution risk, and the key clinical readouts are still 2027-2028, limiting near-term fundamental re-rating.
Key entities
- issuerQuince Therapeutics, Inc.
Clinical-stage biopharma that acquired Orphai and raised net proceeds to fund development through end-2028.
- acquired_companyOrphai Therapeutics
Clinical-stage biotech whose lead program LAM-001 was added to Quince’s pipeline via a stock-for-stock merger.
- pipeline_assetLAM-001
Inhaled rapamycin (sirolimus) mTOR inhibitor; Phase 2b in PH-ILD initiated, with topline expected in Q1 2028.
